nach oben

Erschienen in:

14.04.2018 | Alpha-1-Antitrypsin-Mangel | cme fortbildung

Genetische Ursache einer COPD

Alpha-1-Antitrypsin-Mangel: Pathophysiologie, Diagnostik und Therapie

verfasst von: Dr. med. Sebastian Fähndrich, Nikolas Bernhard, PD Dr. Philipp Lepper, Prof. Dr. Robert Bals

Erschienen in: Pneumo News | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die chronisch obstruktive Lungenerkrankung (COPD) ist eine durch inhalative Noxen hervorgerufene chronische Erkrankung, deren Phänotyp neben Umwelteinflüssen auch durch genetische Ursachen wie einem Alpha-1-Antitrypsin(AAT)-Mangel beeinflusst wird, eine Genotypisierung kann mittels Polymerasekettenreaktion und Sequenzierung erfolgen. Um eine Progression der Erkrankung zu verlangsamen, kann AAT substituiert werden.

https://www.atemwegsliga.de/copd.html?file=tl_files/eigene-dateien/copd/COPD-Leitlinie.pdf

Laurell CB, Eriksson S. The electrophoretic alpha1-globulin pattern of serum in alpha1-antitrypsin deficiency. 1963. COPD. 2013;10 Suppl 1:3–8CrossRef

Konietzko N. [How Carl-Bertil Laurell and Sten Eriksson detected the alpha-1-antitrypsin deficiency 50 years ago and what then came—a somewhat headstrong and personal retrospection]. Pneumologie. 2013;67(10):562–6CrossRef

Blanco I, de Serres FJ, Fernandez-Bustillo E et al. Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1-antitrypsin deficiency in European countries. Eur Respir J. 2006;27(1):77–84CrossRef

Lomas DA, and Parfrey H. Alpha1-antitrypsin deficiency. 4: Molecular pathophysiology. Thorax. 2004;59(6):529–35CrossRef

Greene CM, McElvaney NG. Z alpha-1 antitrypsin deficiency and the endoplasmic reticulum stress response. World J Gastrointest Pharmacol Ther. 2010;1(5):94–101CrossRef

Fairbanks KD, Tavill AS. Liver disease in alpha 1-antitrypsin deficiency: a review. Am J Gastroenterol. 2008;103(8):2136–41; quiz 42CrossRef

Kamimoto T, Shoji S, Hidvegi T et al. Intracellular inclusions containing mutant alpha1-antitrypsin Z are propagated in the absence of autophagic activity. J Biol Chem. 2006;281(7):4467–76CrossRef

Hidvegi T, Mirnics K, Hale P et al. Regulator of G Signaling 16 is a marker for the distinct endoplasmic reticulum stress state associated with aggregated mutant alpha1-antitrypsin Z in the classical form of alpha1-antitrypsin deficiency. J Biol Chem. 2007;282(38):27769–80CrossRef

10.

Perlmutter DH. Clinical manifestations of alpha 1-antitrypsin deficiency. Gastroenterol Clin North Am. 1995;24(1):27–43PubMed

11.

Campbell EJ, Campbell MA, Boukedes SS et al. Quantum proteolysis by neutrophils: implications for pulmonary emphysema in alpha 1-antitrypsin deficiency. J Clin Invest. 1999;104(3):337–44CrossRef

12.

Stockley RA. Alpha 1-antitrypsin: more than just deficiency. Thorax. 2004;59(5):363–4CrossRef

13.

DeMeo DL, Silverman EK. Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax. 2004;59(3):259–64CrossRef

14.

Needham M, Stockley RA. Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history. Thorax. 2004;59(5):441–5CrossRef

15.

Hersh CP, Dahl M, Ly NP et al. Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis. Thorax. 2004;59(10):843–9CrossRef

16.

Brantly ML, Paul LD, Miller BH et al. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis. 1988;138(2):327–36CrossRef

17.

Carrell RW, Lomas DA. Alpha1-antitrypsin deficiency—a model for conformational diseases. N Engl J Med. 2002;346(1):45–53CrossRef

18.

Stoller JK, Snider GL, Brantly ML et al. [American Thoracic Society/European Respiratory Society Statement: Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency]. Pneumologie. 2005;59(1):36–68CrossRef

19.

Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med. 2009;360(26):2749–57CrossRef

20.

Eriksson S, Carlson J, Velez R. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med. 1986;314(12):736–9.CrossRef

21.

Nelson DR, Teckman J, Di Bisceglie AM et al. Diagnosis and management of patients with alpha1-antitrypsin (A1AT) deficiency. Clin Gastroenterol Hepatol. 2012;10(6):575–80CrossRef

22.

Bowlus CL, Willner I, Zern MA et al. Factors associated with advanced liver disease in adults with alpha1-antitrypsin deficiency. Clin Gastroenterol Hepatol. 2005;3(4):390–6CrossRef

23.

Silverman EK, Pierce JA, Province MA et al. Variability of pulmonary function in alpha-1-antitrypsin deficiency: clinical correlates. Ann Intern Med. 1989;111(12):982–91CrossRef

24.

Seersholm N, Kok-Jensen A, Dirksen A. Survival of patients with severe alpha 1-antitrypsin deficiency with special reference to non-index cases. Thorax. 1994;49(7):695–8CrossRef

25.

Parr DG, Stoel BC, Stolk J et al. Pattern of emphysema distribution in alpha1-antitrypsin deficiency influences lung function impairment. Am J Respir Crit Care Med. 2004;170(11):1172–8CrossRef

26.

Gross B, Grebe M, Wencker M et al. New Findings in PiZZ alpha1-antitrypsin deficiency-related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy. Dermatology. 2009;218(4):370–5CrossRef

27.

Mahr AD, Edberg JC, Stone JH et al. Alpha(1)-antitrypsin deficiency-related alleles Z and S and the risk of Wegener’s granulomatosis. Arthritis Rheum. 2010;62(12):3760–7CrossRef

28.

Stoller JK, Sandhaus RA, Turino G et al. Delay in diagnosis of alpha1-antitrypsin deficiency: a continuing problem. Chest. 2005;128(4):1989–94CrossRef

29.

Greulich T, Ottaviani S, Bals R et al. Alpha1-antitrypsin deficiency - diagnostic testing and disease awareness in Germany and Italy. Respir Med. 2013;107(9):1400–8CrossRef

30.

American Thoracic S, European Respiratory S. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818–900CrossRef

31.

Bostrom S, Nilsson I. Telescopic suction tube for microsurgery. Acta Neurochir (Wien). 1992;118(3-4):162–3CrossRef

32.

Costa X, Jardi R, Rodriguez F et al. Simple method for alpha1-antitrypsin deficiency screening by use of dried blood spot specimens. Eur Respir J. 2000;15(6):1111–5CrossRef

33.

McElvaney NG, Burdon J, Holmes M et al. Long-term efficacy and safety of a1 proteinase inhibitor treatment for emphysema caused by severe a1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med. 2017 Jan;5(1):51–60CrossRef

34.

Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet. 2005;365(9478):2225–36CrossRef

35.

Crystal RG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest. 1990;85(5):1343–52CrossRef

36.

Ferrarotti I, Thun GA, Zorzetto M et al. Serum levels and genotype distribution of alpha1-antitrypsin in the general population. Thorax. 2012;67(8):669–74CrossRef

37.

Wewers MD, Casolaro MA, Sellers SE et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987;316(17):1055–62CrossRef

38.

Stoller JK, Aboussouan LS. alpha1-Antitrypsin deficiency. 5: intravenous augmentation therapy: current understanding. Thorax. 2004;59(8):708–12CrossRef

39.

Seersholm N, Wencker M, Banik N et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV₁ in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J. 1997;10(10):2260–3CrossRef

40.

Tomashefski JF Jr., Crystal RG, Wiedemann HP et al. The bronchopulmonary pathology of alpha-1 antitrypsin (AAT) deficiency: findings of the Death Review Committee of the national registry for individuals with Severe Deficiency of Alpha-1 Antitrypsin. Hum Pathol. 2004;35(12):1452–61CrossRef

41.

Wencker M, Fuhrmann B, Banik N et al. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest. 2001;119(3):737–44CrossRef

42.

Chapman KR, Stockley RA, Dawkins C et al. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD. 2009;6(3):177–84CrossRef

43.

Dowson LJ, Guest PJ, Hill SL et al. High-resolution computed tomography scanning in alpha1-antitrypsin deficiency: relationship to lung function and health status. Eur Respir J. 2001;17(6):1097–104CrossRef

44.

Dawkins PA, Dowson LJ, Guest PJ et al. Predictors of mortality in alpha1-antitrypsin deficiency. Thorax. 2003;58(12):1020–6CrossRef

45.

Dirksen A, Dijkman JH, Madsen F et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999;160(5 Pt 1):1468–72CrossRef

46.

Dirksen A, Piitulainen E, Parr DG et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J. 2009;33(6):1345–53CrossRef

47.

Chapman KR, Burdon JG, Piitulainen E et al. Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9991):360–8CrossRef

Titel: Genetische Ursache einer COPD
Alpha-1-Antitrypsin-Mangel: Pathophysiologie, Diagnostik und Therapie
verfasst von: Dr. med. Sebastian Fähndrich
Nikolas Bernhard
PD Dr. Philipp Lepper
Prof. Dr. Robert Bals
Publikationsdatum: 14.04.2018
Verlag: Springer Medizin
Schlagwörter: Alpha-1-Antitrypsin-Mangel
COPD
Lungenemphysem
Erschienen in: Pneumo News / Ausgabe 2/2018
Print ISSN: 1865-5467
Elektronische ISSN: 2199-3866
DOI: https://doi.org/10.1007/s15033-018-0813-2

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Treibt CAP in die Klinik, leidet das Gehirn

Musikhören beim Gehtraining reduziert Dyspnoe bei COPD

Wie gefährlich ist Feinstaub für die Lunge?

Multimodale Reha bei Lungenfibrose effektiv

Hydrokortison bei septischem Schock?

EGFR-TKI-Sequenz beeinflusst Prognose